These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31127079)

  • 21. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated progression from mild cognitive impairment to dementia among APOE ε4ε4 carriers.
    Xu WL; Caracciolo B; Wang HX; Santoni G; Winblad B; Fratiglioni L
    J Alzheimers Dis; 2013; 33(2):507-15. PubMed ID: 23247007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.
    Pettigrew C; Nazarovs J; Soldan A; Singh V; Wang J; Hohman T; Dumitrescu L; Libby J; Kunkle B; Gross AL; Johnson S; Lu Q; Engelman C; Masters CL; Maruff P; Laws SM; Morris JC; Hassenstab J; Cruchaga C; Resnick SM; Kitner-Triolo MH; An Y; Albert M
    Alzheimers Res Ther; 2023 Mar; 15(1):66. PubMed ID: 36978190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of an Alzheimer's disease polygenic risk score to identify mild cognitive impairment in adults in their 50s.
    Logue MW; Panizzon MS; Elman JA; Gillespie NA; Hatton SN; Gustavson DE; Andreassen OA; Dale AM; Franz CE; Lyons MJ; Neale MC; Reynolds CA; Tu X; Kremen WS
    Mol Psychiatry; 2019 Mar; 24(3):421-430. PubMed ID: 29487403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment.
    Fernández-Blázquez MA; Ávila-Villanueva M; Maestú F; Medina M
    J Alzheimers Dis; 2016 Mar; 52(1):271-81. PubMed ID: 27060949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
    Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
    Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
    Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
    Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.
    Euesden J; Gowrisankar S; Qu AX; Jean PS; Hughes AR; Pulford DJ
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32370229
    [No Abstract]   [Full Text] [Related]  

  • 32. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.
    Teixeira AL; Diniz BS; Campos AC; Miranda AS; Rocha NP; Talib LL; Gattaz WF; Forlenza OV
    Neuromolecular Med; 2013 Mar; 15(1):115-21. PubMed ID: 23055000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression from normal cognition to mild cognitive impairment in a diverse clinic-based and community-based elderly cohort.
    Chen Y; Denny KG; Harvey D; Farias ST; Mungas D; DeCarli C; Beckett L
    Alzheimers Dement; 2017 Apr; 13(4):399-405. PubMed ID: 27590706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition.
    Tan CH; Fan CC; Mormino EC; Sugrue LP; Broce IJ; Hess CP; Dillon WP; Bonham LW; Yokoyama JS; Karch CM; Brewer JB; Rabinovici GD; Miller BL; Schellenberg GD; Kauppi K; Feldman HA; Holland D; McEvoy LK; Hyman BT; Bennett DA; Andreassen OA; Dale AM; Desikan RS;
    Acta Neuropathol; 2018 Jan; 135(1):85-93. PubMed ID: 29177679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of Alzheimer's Disease-Associated Genetic Risk with Indicators of Socioeconomic Position on Mild Cognitive Impairment in the Heinz Nixdorf Recall Study.
    Frank M; Hensel J; Baak L; Schramm S; Dragano N; Weimar C; Hoffmann P; Nöthen MM; Erbel R; Jöckel KH; Jokisch M; Schmidt B
    J Alzheimers Dis; 2021; 82(4):1715-1725. PubMed ID: 34219719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.
    Chen XR; Shao Y; Sadowski MJ;
    J Alzheimers Dis; 2021; 82(3):921-937. PubMed ID: 34120907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
    Dunk MM; Driscoll I;
    J Alzheimers Dis; 2022; 85(4):1519-1528. PubMed ID: 34958023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Careful neuropsychological testing reveals a novel genetic marker, GSTO1*C, linked to the pre-stage of Alzheimer's disease.
    Umlauf E; Rappold E; Schiller B; Fuchs P; Rainer M; Wolf B; Zellner M
    Oncotarget; 2016 Jun; 7(26):39108-39117. PubMed ID: 27259244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.